Balance Sheet
Accounts PayablesAccumulated DepreciationAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Pulse Biosciences (PLSE) Accumulated Depreciation (2020 - 2025)

Pulse Biosciences has reported Accumulated Depreciation over the past 6 years, most recently at $4.3 million for Q3 2025.

  • Quarterly results put Accumulated Depreciation at $4.3 million for Q3 2025, up 10.68% from a year ago — trailing twelve months through Sep 2025 was $4.3 million (up 10.68% YoY), and the annual figure for FY2024 was $4.0 million, up 14.15%.
  • Accumulated Depreciation for Q3 2025 was $4.3 million at Pulse Biosciences, up from $4.2 million in the prior quarter.
  • Over the last five years, Accumulated Depreciation for PLSE hit a ceiling of $4.3 million in Q3 2025 and a floor of $2.0 million in Q1 2021.
  • Median Accumulated Depreciation over the past 5 years was $3.2 million (2023), compared with a mean of $3.2 million.
  • Biggest five-year swings in Accumulated Depreciation: grew 28.74% in 2022 and later grew 10.68% in 2025.
  • Pulse Biosciences' Accumulated Depreciation stood at $2.4 million in 2021, then rose by 23.25% to $3.0 million in 2022, then grew by 17.71% to $3.5 million in 2023, then increased by 14.15% to $4.0 million in 2024, then grew by 7.89% to $4.3 million in 2025.
  • The last three reported values for Accumulated Depreciation were $4.3 million (Q3 2025), $4.2 million (Q2 2025), and $4.1 million (Q1 2025) per Business Quant data.